Topical management of striae distensae (stretch marks): prevention and therapy of striae rubrae and albae.
Striae distensae (SD) are common dermal lesions, with significant physical and psychological impact. Many therapeutic modalities are available but none can completely eradicate SD. The most common therapy is the application of topicals used both therapeutically and prophylactically. Even though there are many commercially available topical products, not all have sufficient level of evidence to support their continued use in SD. The aim here was to assess the evidence for the use of topicals in SD and to propose a structured approach in managing SD. A systematic search of published literature and manufacturer website information for topicals in SD was carried out. The results showed that there are few studies (n = 11) which investigate the efficacy of topicals in management of SD. Trofolastin and Alphastria creams demonstrated level-2 evidence of positive results for their prophylactic use in SD. Additionally, tretinoin used therapeutically showed varying results whilst cocoa butter and olive oil did not demonstrate any effect. Overall, there is a distinct lack of evidence for each topical formulation. The majority of topicals failed to mention their effect on early vs. later stages of SD (striae rubrae compared to striae albae) and their role in both prevention and treatment. In conclusion, there is no topical formulation, which is shown to be most effective in eradicating or improving SD. A structured approach in identification and targeted management of symptoms and signs with the appropriate topical is required. Randomized controlled trials are necessary to assess the efficacy of topical products for treatment and prevention of different stages of SD.
Plastic and Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.|Centre for Dermatology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
S
S
Ud-Din
Grosvenor Nuffield Hospital, Chester, UK.
D
D
McGeorge
Plastic and Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.|Centre for Dermatology, Institute of Inflammation and Repair, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
A
A
Bayat
D000287:Administration, Topical; D000481:Allantoin / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D057896:Striae Distensae / Q000517:prevention & control*; D016896:Treatment Outcome; D014801:Vitamin A / Q000008:administration & dosage*; D014810:Vitamin E / Q000008:administration & dosage*
D004338:Drug Combinations; C053233:allantoin, hyaluronic acid, vitamin A, vitamin E drug combinatinon; D014801:Vitamin A; D014810:Vitamin E; D000481:Allantoin; D006820:Hyaluronic Acid